NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Beijing CytoNiche Biotechnology

Beijing CytoNiche Biotechnology

Private
BeijingHealthcare & Life Scienceshttps://www.cytoniche.com/

Last Round

Series B

Extension

Sep 15, 2025

Total Funding Raised

$47M

Company Overview

Beijing CytoNiche Biotechnology is a biotechnology company that provides integrated 3D cell manufacturing platforms and solutions for the cell and gene therapy industry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Smart Manufacturing

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

cell and gene therapyCGT3D cell culturebioreactormicrocarrierscell manufacturingbioprocessingmesenchymal stem cellsregenerative medicineautomated cell expansionGMP manufacturingbiotech equipmentlab automationcell therapy scale-upbiotech manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Beijing CytoNiche Biotechnology Comparables

Compare Beijing CytoNiche Biotechnology with similar companies based on industry and business-model similarity.

Beijing CytoNiche Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shanghai Lepure Biotech Co., Ltd.
76%
Sartorius Aktiengesellschaft
74%
Danaher Corporation
73%

Beijing CytoNiche Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionSep 15, 2025
Series BMar 3, 2022
Series A ExtensionApr 28, 2021
Series ASep 2, 2020
Pre SeedAug 22, 2019

Beijing CytoNiche Biotechnology Investors

Notable investors and investment history

Beijing CytoNiche Biotechnology investors
InvestorRounds
Bencao CapitalSeries B, Series A Extension
德同资本Series B, Series A
Changjiang Growth CapitalPre Seed
CICC CapitalSeries B Extension
北京市新材料产业投资基金Series B Extension
ICBC Financial Asset InvestmentSeries B Extension
Yijing CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 17, 2026

    Grew 60% QoQ from 5 to 8 employees.

  • Sep 2, 2020

    Raised Series A round with investment from 德同资本.

Beijing CytoNiche Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Beijing CytoNiche Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Beijing CytoNiche Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range7
Year Founded2018
Last FundingSep 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.